{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:26:19Z","timestamp":1793895979901,"version":"4.8.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003395","name":"Shanghai Municipal Education Commission","doi-asserted-by":"publisher","award":["2021-01-07-00-07-E00081"],"award-info":[{"award-number":["2021-01-07-00-07-E00081"]}],"id":[{"id":"10.13039\/501100003395","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32330058"],"award-info":[{"award-number":["32330058"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404525"],"award-info":[{"award-number":["82404525"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22501007"],"award-info":[{"award-number":["22501007"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82361168639"],"award-info":[{"award-number":["82361168639"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82125035"],"award-info":[{"award-number":["82125035"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["GZC20240305"],"award-info":[{"award-number":["GZC20240305"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2025T180967"],"award-info":[{"award-number":["2025T180967"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jconrel.2026.115057","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T15:02:17Z","timestamp":1779980537000},"page":"115057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Dexamethasone ameliorates dermatologic adverse effects of PEGylated liposomal doxorubicin"],"prefix":"10.1016","volume":"396","author":[{"given":"Tianhao","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ercan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaru","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyou","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115057_bb0005","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1016\/j.apsb.2022.02.025","article-title":"Current approaches of nanomedicines in the market and various stage of clinical translation","volume":"12","author":"Shan","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2026.115057_bb0010","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: From concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115057_bb0015","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1039\/D4PM00176A","article-title":"Advances in liposomal nanotechnology: from concept to clinics","volume":"1","author":"Senjab","year":"2024","journal-title":"RSC Pharmaceut."},{"key":"10.1016\/j.jconrel.2026.115057_bb0020","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.addr.2020.06.026","article-title":"Lipid nanoparticle technology for therapeutic gene regulation in the liver","volume":"159","author":"Witzigmann","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115057_bb0025","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/j.nano.2018.05.021","article-title":"Lipid based nanocarriers: a translational perspective","volume":"14","author":"Mishra","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.115057_bb0030","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.addr.2020.06.022","article-title":"Recent advancements in liposome technology","volume":"156","author":"Filipczak","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115057_bb0035","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae \u2014 The first FDA-approved nano-drug: Lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115057_bb0040","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.3390\/app15063189","article-title":"Enhancement of EPR effect for passive tumor targeting: current status and future perspectives","volume":"15","author":"Vagena","year":"2025","journal-title":"Appl. Sci."},{"key":"10.1016\/j.jconrel.2026.115057_bb0045","article-title":"Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil\/Caelyx): an updated analysis and future perspective","volume":"4","author":"Gabizon","year":"2025","journal-title":"BMJ Oncol"},{"key":"10.1016\/j.jconrel.2026.115057_bb0050","doi-asserted-by":"crossref","first-page":"446","DOI":"10.12968\/bjha.2021.15.9.446","article-title":"The skin: largest organ of the body","volume":"15","author":"Peate","year":"2021","journal-title":"British J. Healthcare Assistants"},{"key":"10.1016\/j.jconrel.2026.115057_bb0055","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1124\/jpet.103.053413","article-title":"Multiple injections of pegylated liposomal doxorubicin: pharmacokinetics and therapeutic activity","volume":"306","author":"Charrois","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2026.115057_bb0060","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1038\/ncomms4796","article-title":"Nanoparticle exposure in animals can be visualized in the skin and analysed via skin biopsy","volume":"5","author":"Sykes","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115057_bb0065","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1021\/nn901146y","article-title":"In vivo biodistribution and clearance studies using multimodal organically modified silica nanoparticles","volume":"4","author":"Kumar","year":"2010","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115057_bb0070","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jconrel.2009.06.006","article-title":"The effects of PEG grafting level and injection dose on gold nanorod biodistribution in the tumor-bearing mice","volume":"139","author":"Akiyama","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115057_bb0075","doi-asserted-by":"crossref","first-page":"11079","DOI":"10.1039\/c3nr03954d","article-title":"Comprehensive characterizations of nanoparticle biodistribution following systemic injection in mice","volume":"5","author":"Liao","year":"2013","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2026.115057_bb0080","doi-asserted-by":"crossref","first-page":"15863","DOI":"10.1039\/C5NR03626G","article-title":"Nanoparticle distribution during systemic inflammation is size-dependent and organ-specific","volume":"7","author":"Chen","year":"2015","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2026.115057_bb0085","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0005-2736(87)90259-8","article-title":"Uptake of small liposomes by non-reticuloendothelial tissues","volume":"901","author":"Hwang","year":"1987","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.jconrel.2026.115057_bb0090","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0169-409X(96)00476-0","article-title":"Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals","volume":"24","author":"Gabizon","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115057_bb0095","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1001\/archderm.136.12.1475","article-title":"Skin toxic effects of polyethylene glycol\u2013coated liposomal doxorubicin","volume":"136","author":"Lotem","year":"2000","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.jconrel.2026.115057_bb0100","author":"FDA"},{"key":"10.1016\/j.jconrel.2026.115057_bb0105","doi-asserted-by":"crossref","DOI":"10.4081\/oncol.2020.442","article-title":"Management of cytotoxic chemotherapy-induced hand-foot syndrome","volume":"14","author":"Kwakman","year":"2020","journal-title":"Oncol. Rev."},{"key":"10.1016\/j.jconrel.2026.115057_bb0110","article-title":"Reactive oxygen species-mediated inflammation and apoptosis in hand-foot syndrome induced by PEGylated liposomal doxorubicin","volume":"471-480","author":"Hu","year":"2021","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.115057_bb0115","doi-asserted-by":"crossref","first-page":"18769","DOI":"10.1021\/acsnano.4c06638","article-title":"Reciprocal interaction with neutrophils facilitates cutaneous accumulation of liposomes","volume":"18","author":"Ding","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115057_bb0120","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.molimm.2014.06.038","article-title":"Complement activation-related pseudoallergy: A stress reaction in blood triggered by nanomedicines and biologicals","volume":"61","author":"Szebeni","year":"2014","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jconrel.2026.115057_bb0125","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10549-023-06894-3","article-title":"Pegylated liposomal doxorubicin (Duomeisu\u00ae) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study","volume":"199","author":"Jiang","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jconrel.2026.115057_bb0130","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1189\/jlb.0407247","article-title":"Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice","volume":"83","author":"Daley","year":"2008","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jconrel.2026.115057_bb0135","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J Basic Clin Pharm"},{"key":"10.1016\/j.jconrel.2026.115057_bb0140","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of Pegylated Liposomal Doxorubicin","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2026.115057_bb0145","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.4049\/jimmunol.169.7.3555","article-title":"Contrasting impacts of immunosuppressive agents (Rapamycin, FK506, Cyclosporin A, and Dexamethasone) on bidirectional dendritic Cell-T cell interaction during antigen presentation","volume":"169","author":"Matsue","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2026.115057_bb0150","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0024-3205(98)00609-2","article-title":"Dexamethasone inhibits leukocyte migration through endothelial cells towards smooth muscle cells","volume":"64","author":"Hofbauer","year":"1999","journal-title":"Life Sci."},{"key":"10.1016\/j.jconrel.2026.115057_bb0155","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0014-2999(84)90025-6","article-title":"Reduction by dexamethasone of chemotactic activity in inflammatory exudates","volume":"101","author":"Kurihara","year":"1984","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.115057_bb0160","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1006\/cimm.1993.1134","article-title":"Immunosuppression by glucocorticoids: inhibition of production of multiple lymphokines by in Vivo administration of dexamethasone","volume":"149","author":"Kunicka","year":"1993","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.jconrel.2026.115057_bb0165","series-title":"Dexamethasone","author":"Johnson","year":"2022"},{"key":"10.1016\/j.jconrel.2026.115057_bb0170","series-title":"Molecules","article-title":"Dexamethasone attenuates oncostatin M production via suppressing of PI3K\/Akt\/NF-κB signaling in neutrophil-like differentiated HL-60 cells","author":"Han","year":"2022"},{"key":"10.1016\/j.jconrel.2026.115057_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105806","article-title":"Dexamethasone exhibits its anti-inflammatory effects in S. aureus induced microglial inflammation via modulating TLR-2 and glucocorticoid receptor expression","volume":"75","author":"Dey","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jconrel.2026.115057_bb0180","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1365-2249.2000.01373.x","article-title":"Differential anti-inflammatory and anti-oxidative effects of dexamethasone and N-acetylcysteine in endotoxin-induced lung inflammation","volume":"122","author":"Rocks\u00e9n","year":"2000","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jconrel.2026.115057_bb0185","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1093\/annonc\/mdg374","article-title":"Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil\u00ae): possible role in hypersensitivity reactions","volume":"14","author":"Chanan-Khan","year":"2003","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2026.115057_bb0190","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1096\/fj.14-258046","article-title":"A novel CRIg-targeted complement inhibitor protects cells from complement damage","volume":"28","author":"Qiao","year":"2014","journal-title":"FASEB J."},{"key":"10.1016\/j.jconrel.2026.115057_bb0195","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00001813-199801000-00005","article-title":"Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil)","volume":"9","author":"Skubitz","year":"1998","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.jconrel.2026.115057_bb0200","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1172\/JCI116041","article-title":"Recruitment of CD11b\/CD18 to the neutrophil surface and adherence-dependent cell locomotion","volume":"90","author":"Hughes","year":"1992","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2026.115057_bb0205","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0172-2023","article-title":"A narrative review of chemokine receptors CXCR1 and CXCR2 and their role in acute respiratory distress syndrome","volume":"33","author":"Toya","year":"2024","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.jconrel.2026.115057_bb0210","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0092-8674(94)90337-9","article-title":"Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm","volume":"76","author":"Springer","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115057_bb0215","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1182\/blood-2002-08-2396","article-title":"PECAM-1\u2013dependent neutrophil transmigration is independent of monolayer PECAM-1 signaling or localization","volume":"101","author":"O'Brien","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2026.115057_bb0220","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.1016\/j.apsb.2024.07.009","article-title":"Exemplifying interspecies variation of liposome in vivo fate by the effects of anti-PEG antibodies","volume":"14","author":"Wu","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2026.115057_bb0225","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ygyno.2004.05.027","article-title":"Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies","volume":"94","author":"Drake","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2026.115057_bb0230","first-page":"71","article-title":"Skin toxicity after palliative chemotherapy containing pegylated liposomal doxorubicin for ovarian cancer patients, Annals of","volume":"2","author":"Nowara","year":"2013","journal-title":"Palliat. Med."},{"key":"10.1016\/j.jconrel.2026.115057_bb0235","doi-asserted-by":"crossref","first-page":"7187","DOI":"10.12998\/wjcc.v10.i21.7187","article-title":"Effects of glucocorticoids on leukocytes: Genomic and non-genomic mechanisms","volume":"10","author":"Jia","year":"2022","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.jconrel.2026.115057_bb0240","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.3390\/ijms18061249","article-title":"Emerging role of the spleen in the pharmacokinetics of monoclonal antibodies, nanoparticles and exosomes","author":"Cataldi","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.115057_bb0245","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.yexmp.2006.06.007","article-title":"Murine mammary carcinoma 4T1 induces a leukemoid reaction with splenomegaly: Association with tumor-derived growth factors","volume":"82","author":"duPre","year":"2007","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.jconrel.2026.115057_bb0250","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41401-023-01169-5","article-title":"Reexamining the effects of drug loading on the in vivo performance of PEGylated liposomal doxorubicin","volume":"45","author":"Yu","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.jconrel.2026.115057_bb0255","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0959-8049(01)00050-8","article-title":"Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL\/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group","volume":"37","author":"Judson","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jconrel.2026.115057_bb0260","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jocn.2011.02.026","article-title":"Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy","volume":"18","author":"Ananda","year":"2011","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.jconrel.2026.115057_bb0265","series-title":"Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial, Clinical Lymphoma Myeloma and Leukemia","first-page":"152","volume":"15","author":"Oki","year":"2015"},{"key":"10.1016\/j.jconrel.2026.115057_bb0270","doi-asserted-by":"crossref","first-page":"11584","DOI":"10.1021\/acsnano.7b06524","article-title":"Revealing dynamics of accumulation of systemically injected liposomes in the skin by intravital microscopy","volume":"11","author":"Griffin","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115057_bb0275","doi-asserted-by":"crossref","first-page":"6349","DOI":"10.1021\/acsnano.2c00423","article-title":"PEGylated liposomes accumulate in the areas relevant to skin toxicities via passive extravasation across \u201cLeaky\u201d endothelium","volume":"16","author":"Li","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115057_bb0280","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1084\/jem.20181468","article-title":"Neutrophils instruct homeostatic and pathological states in naive tissues","volume":"215","author":"Casanova-Acebes","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2026.115057_bb0285","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1038\/s41467-024-50568-7","article-title":"Kupffer cells determine intrahepatic traffic of PEGylated liposomal doxorubicin","volume":"15","author":"Jiang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115057_bb0290","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3109\/08982109409037065","article-title":"Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in Stealth\u00ae Liposomes (Doxil\u00ae)","volume":"4","author":"Working","year":"1994","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.jconrel.2026.115057_bb0295","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2249.1990.tb03310.x","article-title":"The influence of prednisolone on the recirculation of peripheral blood lymphocytes in vivo","volume":"80","author":"Bloemena","year":"1990","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jconrel.2026.115057_bb0300","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s13577-012-0057-0","article-title":"Pathogenesis of hand-foot syndrome induced by PEG-modified liposomal doxorubicin","volume":"26","author":"Yokomichi","year":"2013","journal-title":"Hum. Cell"},{"key":"10.1016\/j.jconrel.2026.115057_bb0305","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/096032719901800103","article-title":"Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs","volume":"18","author":"Amantea","year":"1999","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.jconrel.2026.115057_bb0310","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/sj.clpt.1996.111","article-title":"PK\/PD of pegylated-liposomal doxorubicin (LD) and the appearance of dermal lesions in dogs","volume":"59","author":"Newman","year":"1996","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2026.115057_bb0315","first-page":"269","article-title":"Quantitation of beta 1c\/1A globulin (C3) in inbred mice: variation dependent upon strain, age, sex and environment","volume":"53","author":"Natsuume-Sakai","year":"1977","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"10.1016\/j.jconrel.2026.115057_bb0320","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/milmed\/usy412","article-title":"Early complement and fibrinolytic activation in a rat model of blast-induced multi-organ damage","volume":"184","author":"Yang","year":"2019","journal-title":"Mil. Med."},{"key":"10.1016\/j.jconrel.2026.115057_bb0325","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/jvim.17008","article-title":"Serum concentrations of complement C3 and C4 in dogs with idiopathic epilepsy","volume":"38","author":"Kang","year":"2024","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.jconrel.2026.115057_bb0330","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/978-1-62703-724-2_6","article-title":"Purification and characterization of human and mouse complement C3","volume":"1100","author":"Ruseva","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jconrel.2026.115057_bb0335","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0022-1759(89)90088-4","article-title":"Mouse strains with typical mammalian levels of complement activity","volume":"125","author":"Ong","year":"1989","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jconrel.2026.115057_bb0340","first-page":"96","article-title":"Practical murine hematopathology: a comparative review and implications for research","volume":"65","author":"O'Connell","year":"2015","journal-title":"Comp Med"},{"key":"10.1016\/j.jconrel.2026.115057_bb0345","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/ame2.12041","article-title":"Reference values for selected hematological, biochemical and physiological parameters of Sprague-Dawley rats at the Animal House, Faculty of Medicine, University of Colombo, Sri Lanka","volume":"1","author":"Delwatta","year":"2018","journal-title":"Animal Model Exp Med"},{"key":"10.1016\/j.jconrel.2026.115057_bb0350","series-title":"Evaluation of the Blood Neutrophil-to-Lymphocyte Ratio (NLR) as a Diagnostic and Prognostic Biomarker in Dogs with Portosystemic Shunt","first-page":"80","author":"Becher","year":"2024"},{"key":"10.1016\/j.jconrel.2026.115057_bb0355","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/imr.13154","article-title":"Human neutrophils \u2260 murine neutrophils: Does it matter?","volume":"314","author":"Nauseef","year":"2023","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jconrel.2026.115057_bb0360","doi-asserted-by":"crossref","first-page":"1358796","DOI":"10.1155\/jt\/1358796","article-title":"Dexrazoxane protects against hand\u2013foot syndrome\u2013like skin damage in pegylated liposomal doxorubicin-treated mice","volume":"2026","author":"Nishida","year":"2026","journal-title":"J. Toxicol."},{"key":"10.1016\/j.jconrel.2026.115057_bb0365","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jconrel.2020.01.018","article-title":"Natural IgM dominates in vivo performance of liposomes","volume":"319","author":"Ding","year":"2020","journal-title":"J. Control. Release"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926004608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926004608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:48:27Z","timestamp":1793893707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926004608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":73,"alternative-id":["S0168365926004608"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115057","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dexamethasone ameliorates dermatologic adverse effects of PEGylated liposomal doxorubicin","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115057"}}